FDA approves CVRx Barostim Neo System for advanced heart failure symptoms
CVRx, a Maple Grove-based medical device company, has secured approval for its implantable technology – Barostim Neo System from the US Food and Drug Administration (FDA) to improve symptoms in patients with advanced heart failure. As per the FDA approval for the CVRx Barostim Neo System, the medical device has to be used in patients […]
The post FDA approves CVRx Barostim Neo System for advanced heart failure symptoms appeared first on PharmaNewsDaily.com.
Bio-Thera Solutions begins phase 1 trial for Simponi biosimilar BAT2506
Chinese biotech company Bio-Thera Solutions has started dosing in a phase 1 clinical trial to study the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Janssen Biotech’s Simponi (golimumab). The early-stage clinical study is a randomized two-arm, parallel-group trial that will have nearly 182 healthy volunteers. Each of the patients will be subjected to […]
The post Bio-Thera Solutions begins phase 1 trial for Simponi biosimilar BAT2506 appeared first on PharmaNewsDaily.com.
Neuropore gets FDA orphan drug designation for NPT520-34 for ALS
Neuropore Therapies has secured orphan drug designation for NPT520-34 from the US Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). The California-based biopharma company said that the orphan drug designation will enable the development of NPT520-34 in the treatment of the debilitating medical condition for which there are not many […]
The post Neuropore gets FDA orphan drug designation for NPT520-34 for ALS appeared first on PharmaNewsDaily.com.
PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial
PAOLA 1 trial results : Lynparza (olaparib), a cancer drug which was jointly developed by AstraZeneca and MSD, in combination with bevacizumab, met the primary endpoint of the phase 3 PAOLA 1 clinical trial in patients with advanced ovarian cancer. The PAOLA 1 primary endpoint is the statistically-significant and clinically-meaningful improvement shown by Lynparza plus […]
The post PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial appeared first on PharmaNewsDaily.com.
TB Alliance bags Pretomanid FDA approval for highly drug-resistant TB
Pretomanid FDA approval : Non-profit organization TB Alliance has secured approval for Pretomanid Tablets in combination with bedaquiline and linezolid from the US Food & Drug Administration (FDA) for the treatment of highly drug-resistant forms of tuberculosis. The combination regimen was approved by the FDA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD […]
The post TB Alliance bags Pretomanid FDA approval for highly drug-resistant TB appeared first on PharmaNewsDaily.com.
US gene therapy company Renovacor raises $11m for BAG3 gene therapy
US gene therapy company Renovacor, which is engaged in developing BAG3 gene therapy and other gene therapies for cardiovascular disease, has raised $11 million through a Series A financing round led jointly by Novartis Venture Fund, Broadview Ventures, and BioAdvance. New Leaf Venture Partners and Innogest Capital also joined the Series A funding round. The […]
The post US gene therapy company Renovacor raises $11m for BAG3 gene therapy appeared first on PharmaNewsDaily.com.
Landos Biopharma secures $60m in Series B financing round
Landos Biopharma, a US clinical-stage pharma company focused on the discovery and development of oral therapeutics for autoimmune diseases, has closed a $60 million Series B financing round. The financing round was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund). Osage University Partners and PBM Capital were […]
The post Landos Biopharma secures $60m in Series B financing round appeared first on PharmaNewsDaily.com.
Jazz Pharmaceuticals acquires Cavion, developer of essential tremor drugs
Jazz Pharmaceuticals acquisition of Cavion : Irish pharma company Jazz Pharmaceuticals has acquired US-based clinical-stage pharma company Cavion, a developer of essential tremor drugs, in a deal worth up to $312.5 million as per the latest pharma acquisition news. Based in Cambridge, Massachusetts, Cavion is engaged in developing therapies aimed at regulating the T-type calcium […]
The post Jazz Pharmaceuticals acquires Cavion, developer of essential tremor drugs appeared first on PharmaNewsDaily.com.
AtriCure to acquire Californian medical device company SentreHEART
AtriCure acquisition of SentreHEART : Afib device manufacturer AtriCure has agreed to acquire California-based medical device company SentreHEART in a deal worth up to about $300 million. Based in Ohio, AtriCure makes devices for the treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management. AtriCure’s Isolator Synergy Ablation System is the first and […]
The post AtriCure to acquire Californian medical device company SentreHEART appeared first on PharmaNewsDaily.com.
Neoleukin completes merger with Aquinox Pharmaceuticals
US biopharma company Neoleukin Therapeutics has wrapped up a previously announced merger with Canadian pharma company Aquinox Pharmaceuticals. Headquartered in Vancouver, Aquinox Pharmaceuticals focused on discovering and developing novel therapeutics for conditions related to inflammation, inflammatory pain, and blood cancers. On the other hand, Neoleukin creates next-generation immunotherapies by using its de novo protein design […]
The post Neoleukin completes merger with Aquinox Pharmaceuticals appeared first on PharmaNewsDaily.com.